Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2014.327
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Breast Carcinoma With Amplified HER2: A Gene Expression Signature Specific for Trastuzumab Resistance and Poor Prognosis

Modern Pathology
Forensic MedicinePathology
2010English

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

Cancer Research
Cancer ResearchOncology
2011English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy